Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media 3 Stocks Under $5 With Strong Analyst Upside PotentialSubmitted by Chris Markoch. Article Posted: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace the risk-reward trade-off. Stocks trading under $5 often carry elevated risk: many of these companies are unprofitable, some generate little to no revenue, and most are small caps. Small-cap stocks have been beaten up over the past several years, and even with the Russell 2000 showing some signs of recovery, that strength hasn't been uniform across the broader small-cap sector. That could change in 2026 if the economic outlook continues to improve, drawing money back into speculative names. As always, quality matters — one simple filter is positive analyst sentiment. The three stocks below trade under $5, let investors start a sizable position with a modest outlay, and have analyst-backed upside potential over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be among the winners in 2026, but that hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a super app that combines elements of technology, e-commerce and fintech. Part of the recent pullback stems from uncertainty around its proposed merger with Indonesian ride-hail competitor GoTo. The deal isn't final and remains subject to potential regulatory and legislative changes in Indonesia that could affect the company's earnings potential there. Grab also missed expectations on the top line in its Q4 2025 earnings report. Still, revenue grew 19% year-over-year, and the year marked the company's first full year of profitability. Analysts anticipate roughly 120% earnings growth over the next 12 months, which helps explain the continued bullish sentiment. GRAB has a consensus price target of $6.47, about 54% above its current price. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotech sector for asymmetric payoff potential. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that fits the classic penny-stock definition — at the time of writing it traded just above $0.60 per share. VXRT has limited analyst coverage, but the recent rating is a Buy with a $2 price target. That low coverage is common for clinical-stage biotechs: Vaxart's candidates are still in clinical trials, so near-term commercial revenue is limited. The company's upside is tied to its oral vaccine platform, which targets influenza, norovirus and COVID-19. Beyond the convenience of needle-free delivery, Vaxart says its platform may elicit a broader immune response that could translate into wider protection compared with traditional routes. Only about 18% of VXRT's shares are held by institutions, but dollar-volume data indicates inflows have outpaced outflows by nearly 10-to-1, suggesting a concentrated interest among active buyers. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% so far in 2026, but a longer view shows the stock is up more than 66% over the past 12 months. That framing makes the recent sell-off look like a pullback amid a market rotation away from unprofitable companies. ThredUp operates an online consignment and thrift marketplace that has gained traction with Gen Z, a trend reflected in its results. In its most recent quarter, revenue rose 12.5% year-over-year. The company cites a GlobalData 2025 market survey forecasting U.S. secondhand market gross merchandise value to grow at a compound annual growth rate (CAGR) of 9% through 2029, which would support a favorable long-term backdrop. Institutional investors own an impressive ~89% of TDUP; dollar-volume buying has outpaced selling about 2-to-1, and the number of buyers has exceeded sellers roughly 3-to-1. However, short interest sits near 17%, a factor that can add short-term volatility. The consensus price target from six analysts is $12.50, which would represent an increase of roughly 190% from the stock's price at the time of writing.
| 
